Titanovo Logo
Back to Cell Types

NCI-H69Homo sapiens (Human)Cancer cell line

Also known as: NCI-H-69, NCI H69, H69, H-69, NCIH69, NCI-HUT-69, H69/P, NCI-H69C, H69C, H69c

🤖 AI SummaryBased on 14 publications

Quick Overview

Human small cell lung cancer cell line with known genetic alterations.

Detailed Summary

The NCI-H69 cell line is a human small cell lung cancer (SCLC) cell line derived from a pleural effusion. It is widely used in cancer research due to its well-characterized genetic profile, including mutations in key oncogenes and tumor suppressor genes. This cell line has been extensively studied for its role in understanding the molecular mechanisms of SCLC, particularly in the context of drug resistance and therapeutic targeting. Research on NCI-H69 has contributed to the identification of potential therapeutic targets such as PARP1 and EZH2, which are implicated in SCLC progression. The cell line is also notable for its use in studies involving genomic alterations, including copy number variations and mutations, which have provided insights into the genetic basis of SCLC. Additionally, NCI-H69 has been utilized in studies examining the relationship between genetic alterations and drug sensitivity, making it a valuable model for preclinical cancer research.

Research Applications

Genomic alterations in SCLCDrug resistance mechanismsTherapeutic target identificationMolecular mechanisms of SCLC progression

Key Characteristics

Mutations in key oncogenes and tumor suppressor genesKnown involvement in PARP1 and EZH2 pathwaysUsed in studies of drug sensitivity and resistanceExtensively characterized for genomic and molecular profiles
Generated on 6/17/2025

Basic Information

Database IDCVCL_1579
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age55
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung small cell carcinoma
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeATCC
Source IDACH-000358_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimplePIK3CAp.Gly106_Arg108del (c.317_325delGGCAACCGT)Heterozygous-from parent cell line NCI-N592/IL2
MutationSimpleRB1p.Glu748Ter (c.2242G>T)Homozygous-from parent cell line NCI-N592/IL2
MutationSimpleTP53p.Glu171Ter (c.511G>T)Unspecified-PubMed=9887230, PubMed=7503188

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,12
D13S317
12
D16S539
11
D18S51
12
D19S433
15,15.2
D21S11
30,31.2
D2S1338
17
D3S1358
16
D5S818
11,13
D7S820
9
D8S1179
13
FGA
24
Penta D
9,11
Penta E
12
TH01
8,9
TPOX
10
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

DOIPubMedPMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Comparative proteogenomics profiling of non-small and small lung carcinoma cell lines using mass spectrometry.

Wu J.-Y., Hao Z.-F., Ma C., Li P.-F., Dang L.-Y., Sun S.-S.

PeerJ 8:e8779.1-e8779.19(2020).

DOIPubMedPMC

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Minna J.D., Wistuba I.I., Pertsemlidis A.

Oncotarget 9:29601-29618(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

DOIPubMedPMC

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

Lucchi M., Smith W.I. Jr., Meltzer P.S., Wang Y.-S., Giaccone G.

Proc. Natl. Acad. Sci. U.S.A. 107:13040-13045(2010).

DOIPubMedPMC

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

DOIPubMedPMC

Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping.

Rojo F., Arumi-Uria M., Serrano S., Albanell J., Sole F.

Cancer Genet. Cytogenet. 191:97-101(2009).

DOIPubMed

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.

Shibata T., Kokubu A., Tsuta K., Hirohashi S.

Cancer Lett. 283:203-211(2009).

DOIPubMed

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Sauter G., Lesniewski R., Semizarov D.

Mol. Cancer Res. 5:331-339(2007).

DOIPubMed

Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer.

Hayashi S., Aozasa K., Kawase I.

Oncogene 22:674-687(2003).

DOIPubMed

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Wolf E., Gabius H.-J.

J. Cancer Res. Clin. Oncol. 127:375-386(2001).

DOIPubMed

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

DOIPubMed

Identification and characterisation in vitro of cells with a non-SCLC cell-like phenotype derived from a continuous SCLC cell line.

McNicol A.M.

Anticancer Res. 11:1687-1695(1991).

PubMed

Novel antigens characteristic of neuroendocrine malignancies.";

Boerman O.C., Ramaekers F.C.S.

Cancer 67:619-633(1991).

DOIPubMed

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Saijo N.

Cancer Chemother. Pharmacol. 27:263-270(1991).

DOIPubMed

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

J. Natl. Cancer Inst. 82:1420-1426(1990).

DOIPubMed

Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines.

Carney D.N., Vooijs G.P., Ramaekers F.C.S.

J. Cell Sci. 91:91-108(1988).

DOIPubMed

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Skovsgaard T., Hansen H.H.

Br. J. Cancer 60:838-844(1989).

DOIPubMedPMC

Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling.

Little J.B., McConkie-Rosell A., Buckley E.G., Dryja T.P.

N. Engl. J. Med. 321:1689-1695(1989).

DOIPubMed

Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Moody T.W., Zweig M.H., Minna J.D.

Cancer Res. 45:2913-2923(1985).

PubMed

Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Gazdar A.F., Carney D.N., Nau M.M., Minna J.D.

Cancer Res. 45:2924-2930(1985).

PubMed

Cytogenetics of human small cell lung cancer.";

Whang-Peng J., Lee E.C.

Recent Results Cancer Res. 97:37-46(1985).

DOIPubMed

Oncogene amplification and chromosomal abnormalities in small cell lung cancer.

Ibson J.M., Waters J.J., Twentyman P.R., Bleehen N.M., Rabbitts P.H.

J. Cell. Biochem. 33:267-288(1987).

DOIPubMed

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.

Bunn P.A. Jr., Guccion J.G., Minna J.D.

Cancer Res. 40:3502-3507(1980).

PubMed

Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.

Mitchell J.B.

J. Natl. Cancer Inst. 73:801-807(1984).

DOIPubMed

Monoclonal antibodies that demonstrate specificity for several types of human lung cancer.

Cuttitta F., Rosen S.T., Gazdar A.F., Minna J.D.

Proc. Natl. Acad. Sci. U.S.A. 78:4591-4595(1981).

DOIPubMedPMC

High levels of intracellular bombesin characterize human small-cell lung carcinoma.

Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.

Science 214:1246-1248(1981).

DOIPubMed

Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies.

Gazdar A.F., Minna J.D.

Cancer Res. 44:2052-2061(1984).

PubMed

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

Lofters W.S., Flynn T.G.

Cancer 75:2442-2451(1995).

DOIPubMed

A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene.

Twentyman P.R.

J. Natl. Cancer Inst. 86:110-117(1994).

DOIPubMed

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

J. Cancer Res. Clin. Oncol. 120:143-148(1994).

DOIPubMed

Insulin-like growth factor expression in human cancer cell lines.";

Grimley C., Battey J., Mulshine J.L., Cuttitta F.

J. Biol. Chem. 271:11477-11483(1996).

DOIPubMed

Tumorigenicity, invasion and metastasis of the small cell lung cancer cell line NCI-H69 and two derivative lines MOG-H69V and MOG-H69VZ.

Khan M.Z., McNicol A.M., Freshney R.I.

Anticancer Res. 16:1659-1669(1996).

PubMed

Lack of c-mpl proto-oncogene transcripts and growth-stimulatory effects of thrombopoietin on human small cell lung cancer cell lines.

Shinohara A., Shimizu E., Takada M., Sone S.

Oncology 53:426-434(1996).

DOIPubMed

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

DOIPubMed

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Ihde D.C., Gazdar A.F.

J. Cell. Biochem. Suppl. 24:210-217(1996).

DOIPubMed

Cellular radiosensitivity of small-cell lung cancer cell lines.";

Krarup M., Poulsen H.S., Spang-Thomsen M.

Int. J. Radiat. Oncol. Biol. Phys. 38:191-196(1997).

DOIPubMed

Small cell lung cancer can express CD34 antigen.";

Hiraki A., Ueoka H., Harada M.

Anticancer Res. 17:3627-3632(1997).

PubMed

Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma.

Rabbitts P.H., Sundaresan V., Hofstra R.M.W., Eng C.

Genes Chromosomes Cancer 21:326-332(1998).

DOIPubMed

In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.

Poulsen H.S.

Br. J. Cancer 78:631-640(1998).

DOIPubMedPMC

Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.

Cole S.P.C., Gerlach J.H.

Clin. Cancer Res. 3:115-122(1997).

PubMed

Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.

Tang X.X., Brodeur G.M., Campling B.G., Ikegaki N.

Clin. Cancer Res. 5:455-460(1999).

PubMed

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

DOIPubMed

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

DOIPubMed

Web Resources

tcpaportal.orgatcc.org